MICAT: A Melanoma Collaborative Trial Platform for the Future
Melanoma International Collaboration for Adaptive Trials (MICAT), a collaborative platform trial using adaptive trial design to test new agents and combinations in biomarker defined treatments for post-PD-1 treated metastatic melanoma, is transforming the development of melanoma therapies.
Building on Advances from I-SPY 2
I-SPY 2 is a Phase II screening trial that accelerates identification of active agents or combinations of drugs, and predictive biomarkers in the neo-adjuvant breast cancer treatment setting.
MICAT is a global academic-industry collaboration with advocacy and regulatory participation which will test multiple lines of therapy. MICAT will use adaptive statistical methods to enhance strategic decisions in Phase II and Phase III oncology trials. This patient-centric trial will bring effective therapies to the market sooner.
The MICAT Collaboration
The MICAT collaborative platform is designed to increase the speed of decision-making about:
- Specific drug or combination of compounds
- Relevant biomarkers
- Disease progression
- Optimal intervention strategies related to patient subpopulations
|MICAT Research Goals|